These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37914171)

  • 21. Ursodeoxycholate inhibits mast cell activation and reverses biliary injury and fibrosis in Mdr2
    Meng F; Kennedy L; Hargrove L; Demieville J; Jones H; Madeka T; Karstens A; Chappell K; Alpini G; Sybenga A; Invernizzi P; Bernuzzi F; DeMorrow S; Francis H
    Lab Invest; 2018 Nov; 98(11):1465-1477. PubMed ID: 30143751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sclerosing cholangitis in a patient treated with nivolumab.
    Talbot S; MacLaren V; Lafferty H
    BMJ Case Rep; 2021 May; 14(5):. PubMed ID: 34049893
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
    Mitchell SA; Bansi DS; Hunt N; Von Bergmann K; Fleming KA; Chapman RW
    Gastroenterology; 2001 Oct; 121(4):900-7. PubMed ID: 11606503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ursodeoxycholic Acid Therapy in Pediatric Primary Sclerosing Cholangitis: Predictors of Gamma Glutamyltransferase Normalization and Favorable Clinical Course.
    Deneau M; Perito E; Ricciuto A; Gupta N; Kamath BM; Palle S; Vitola B; Smolka V; Ferrari F; Amir AZ; Miloh T; Papadopoulou A; Mohan P; Mack C; Kolho KL; Iorio R; El-Matary W; Venkat V; Chan A; Saubermann L; Valentino PL; Shah U; Miethke A; Lin H; Jensen MK
    J Pediatr; 2019 Jun; 209():92-96.e1. PubMed ID: 30878206
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid.
    Hayashi H; Higuchi T; Ichimiya H; Hishida N; Sakamoto N
    Gastroenterology; 1990 Aug; 99(2):533-5. PubMed ID: 2365199
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
    Weber JS; Postow M; Lao CD; Schadendorf D
    Oncologist; 2016 Oct; 21(10):1230-1240. PubMed ID: 27401894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Treatment of primary biliary cirrhosis and primary sclerosing cholangitis: use of ursodeoxycholic acid.
    Lee YM; Kaplan MM
    Curr Gastroenterol Rep; 1999; 1(1):38-41. PubMed ID: 10980925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Overlap syndrome of primary biliary cholangitis and primary sclerosing cholangitis: two case reports.
    Yacoub H; Ben Azouz S; Hassine H; Debbabi H; Cherif D; Ghayeb F; Boukriba S; Kchir H; Maamouri N
    J Med Case Rep; 2023 Apr; 17(1):169. PubMed ID: 37106413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delayed immune-related sclerosing cholangitis after discontinuation of pembrolizumab: A case report.
    Tanaka T; Sakai A; Tsujimae M; Yamada Y; Kobayashi T; Masuda A; Kodama Y
    World J Gastroenterol; 2022 Jul; 28(28):3732-3738. PubMed ID: 36161046
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Case report: anti-proteinase 3 antibody activity in a patient with primary sclerosing cholangitis: clinical remission following ursodeoxycholic acid therapy.
    Wong SS; Lawton JW
    J Gastroenterol Hepatol; 1996 Dec; 11(12):1161-3. PubMed ID: 9034936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid is associated with improved long-term outcome in patients with primary sclerosing cholangitis.
    Arizumi T; Tazuma S; Isayama H; Nakazawa T; Tsuyuguchi T; Takikawa H; Tanaka A;
    J Gastroenterol; 2022 Nov; 57(11):902-912. PubMed ID: 36068441
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial.
    Beuers U; Spengler U; Kruis W; Aydemir U; Wiebecke B; Heldwein W; Weinzierl M; Pape GR; Sauerbruch T; Paumgartner G
    Hepatology; 1992 Sep; 16(3):707-14. PubMed ID: 1505913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A case with life-threatening secondary sclerosing cholangitis caused by nivolumab.
    Yoshikawa Y; Imamura M; Yamaoka K; Kosaka Y; Murakami E; Morio K; Fujino H; Nakahara T; Okamoto W; Yamauchi M; Kawaoka T; Tsuge M; Hiramatsu A; Hayes CN; Aikata H; Fujitaka K; Arihiro K; Hattori N; Chayama K
    Clin J Gastroenterol; 2021 Feb; 14(1):283-287. PubMed ID: 33200345
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis.
    Komatsu K; Shimosegawa T; Kikuchi S; Uchi M; Maruhama Y; Kisara N; Ueno Y; Toyota T
    Intern Med; 2000 Dec; 39(12):1049-53. PubMed ID: 11197788
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Secondary sclerosing cholangitis: after injection of formaldehyde into hydatid cysts in the liver.
    Tsimoyiannis EC; Grantzis E; Moutesidou K; Lekkas ET
    Eur J Surg; 1995 Apr; 161(4):299-300. PubMed ID: 7612776
    [No Abstract]   [Full Text] [Related]  

  • 40. [Primary sclerosing cholangitis and systemic lupus erythematosus].
    Audan A; Bruley Des Varannes S; Georgelin T; Sagan C; Cloarec D; Serraz H; Le Bodic L
    Gastroenterol Clin Biol; 1995 Jan; 19(1):123-6. PubMed ID: 7720973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.